Based on the measurements of operating efficiency obtained from Lexaria Bioscience's historical financial statements, Lexaria Bioscience Corp is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Lexaria Bioscience's Common Stock Shares Outstanding is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to climb to about 9.3 M in 2024, despite the fact that Net Debt is likely to grow to (6 M). Key indicators impacting Lexaria Bioscience's financial strength include:
The financial analysis of Lexaria Bioscience is a critical element in measuring its lifeblood. Investors should not minimize Lexaria Bioscience's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(5.51 Million)
Lexaria
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Begin Period Cash Flow
Depreciation
Other Non Cash Items
Change To Account Receivables
Stock Based Compensation
Change To Inventory
Sale Purchase Of Stock
Total Cashflows From Investing Activities
Other Cashflows From Investing Activities
Investments
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Common Stock
Short Long Term Debt Total
Current Deferred Revenue
Net Receivables
Short Term Debt
Inventory
Non Currrent Assets Other
Intangible Assets
Capital Surpluse
Property Plant Equipment
Net Invested Capital
Net Working Capital
Short Term Investments
Accumulated Other Comprehensive Income
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Total Revenue
Gross Profit
Cost Of Revenue
Selling General Administrative
Selling And Marketing Expenses
Research Development
Net Income Applicable To Common Shares
Net Interest Income
Net Income From Continuing Ops
Reconciled Depreciation
Minority Interest
Probability Of Bankruptcy
Understanding current and past Lexaria Bioscience Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Lexaria Bioscience's financial statements are interrelated, with each one affecting the others. For example, an increase in Lexaria Bioscience's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Lexaria Bioscience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lexaria Bioscience Corp. Check Lexaria Bioscience's Beneish M Score to see the likelihood of Lexaria Bioscience's management manipulating its earnings.
Lexaria Bioscience Stock Summary
Lexaria Bioscience competes with Lexaria Bioscience, GeoVax Labs, Reviva Pharmaceuticals, and Immatics Biotechnologies. Lexaria Bioscience Corp. operates in the drug delivery platform business. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. Lexaria Bioscience is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Lexaria Bioscience's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Lexaria Bioscience's current stock value. Our valuation model uses many indicators to compare Lexaria Bioscience value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lexaria Bioscience competition to find correlations between indicators driving Lexaria Bioscience's intrinsic value. More Info.
Lexaria Bioscience Corp is rated third overall in return on equity category among its peers. It also is rated third overall in return on asset category among its peers . At this time, Lexaria Bioscience's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Lexaria Bioscience by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Lexaria Bioscience Corp Systematic Risk
Lexaria Bioscience's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lexaria Bioscience volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Lexaria Bioscience Corp correlated with the market. If Beta is less than 0 Lexaria Bioscience generally moves in the opposite direction as compared to the market. If Lexaria Bioscience Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lexaria Bioscience Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lexaria Bioscience is generally in the same direction as the market. If Beta > 1 Lexaria Bioscience moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Lexaria Bioscience is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Lexaria has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Lexaria Bioscience's financials are consistent with your investment objective using the following steps:
Review Lexaria Bioscience's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand Lexaria Bioscience's liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare Lexaria Bioscience's financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Lexaria Bioscience's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in Lexaria Bioscience Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lexaria Bioscience's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lexaria Bioscience growth as a starting point in their analysis.
Lexaria Bioscience November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lexaria Bioscience help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lexaria Bioscience Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lexaria Bioscience Corp based on widely used predictive technical indicators. In general, we focus on analyzing Lexaria Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lexaria Bioscience's daily price indicators and compare them against related drivers.
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.